Because of the direct impact DM and related cardiometabolic disorders have on CVD, the American Heart Association (AHA) is building a multifaceted initiative to (1) unite the primary care, cardiology, endocrinology, and other specialty care provider communities in a comprehensive approach to caring for and treating patients with cardiometabolic conditions such as DM; (2) educate and empower people living with cardiometabolic disorders and DM to better self-manage their condition(s) and improve their cardiovascular health.
I
n the United States, 23.4 million adults have physiciandiagnosed diabetes mellitus (DM), 1 81.6 million have prediabetes, and 18 000 people under age 20 years are diagnosed with type 1 DM each year. 2 Approximately 90% to 95% of all adult DM cases are type 2. 2 As such, data mentioned throughout will primarily comprise patients with type 2 DM. Patients with DM are 2 to 4 times more likely to die of cardiovascular disease (CVD) than patients without DM. The prevalence of patients living with DM and prediabetes continues to increase, putting these individuals at greater risk of having a heart attack or stroke. Often patients with DM have multiple other health problems and must also manage other cardiometabolic health risk factors such as obesity, hypertension, and high cholesterol. Because of the direct impact DM and related cardiometabolic disorders have on CVD, the American Heart Association (AHA) is building a multifaceted initiative to (1) unite the primary care, cardiology, endocrinology, and other specialty care provider communities in a comprehensive approach to caring for and treating patients with cardiometabolic conditions such as DM; (2) educate and empower people living with cardiometabolic disorders and DM to better self-manage their condition(s) and improve their cardiovascular health.
By expanding AHA's efforts to include initiatives and programs to reduce the prevalence and impact of cardiometabolic risk factors (such as prediabetes) and conditions (such as DM), the AHA will progress toward its mission of building healthier lives, free of cardiovascular diseases and stroke.
To launch this new initiative, AHA held its first Cardiometabolic Health and Diabetes Summit on December 5, 2017 , in Dallas, Texas. The objective was to identify and prioritize opportunities to improve cardiometabolic health and DM care in the United States ( Figure 1 ).
The AHA is a leader in developing quality clinical care programs; cardiovascular population-based health programs; and public awareness, education, and empowerment campaigns that focus on undertreated populations. The AHA brought together experts from leading US healthcare, patient, professional, government, and public organizations to discuss a comprehensive approach for reducing cardiometabolic risk and improving comprehensive DM care. Twenty-one organizations were represented by more than 100 attendees.
Summit structure
The Summit format included keynote speakers from the Centers for Disease Control and Prevention (CDC) and the National Hispanic Medical Association. Subject matter experts participated in panel discussions focusing on healthcare systems and quality improvement; patient and community awareness and empowerment; and leveraging technology to advance patient care. Presenters addressed these issues from the perspective of the clinician, patient, community, and public health. Small-group breakout sessions generated a priority list of activities addressing gaps and needs for the AHA and its collaborators to address over the short and long term. Many participants and organizations provided poster for Prevention, further detailed the increasing prevalence of hypertension, DM, prediabetes, and cholesterol in the United States, as well as the increasing percentage of patients who have 2 or more of these conditions. Recognizing this increasing impact, AHA leadership framed the importance of a comprehensive approach to the treatment and management of patients with DM and prediabetes to optimize cardiometabolic risk factors, and ultimately lower cardiovascular risk. Figure 2 is adapted to illustrate the interplay between what the AHA calls "Life's Simple 7" and cardiometabolic risk factors that affect a person's likelihood of developing CVD. 3 (Life's Simple 7 is the name for the factors and behaviors proven to build toward ideal cardiovascular health: stop smoking, eat better, get active, maintain a healthy weight, manage blood pressure, control cholesterol, and control blood glucose).
Plenary Session Summary: Addressing US Health Disparities in DM Care
The CDC has been at the forefront of evidence-based interventions for the US healthcare and public health systems to help reduce the incidence and complications of DM and CVD. Almost 40% of all Americans have obesity, which translates to 1.5 million new cases of DM each year. 1 The annual medical cost of obesity was estimated to be $147 billion in 2008 in the United States. There are dramatic disparities in the prevalence of DM across racial and ethnic groups. DM prevalence is highest among American Indians, Alaska Natives, Hispanics, and non-Hispanic blacks. In contrast, Asian and white non-Hispanic prevalence rates are 50% lower than those for other racial and ethnic groups. The CDC's approach focuses on health equity, lifestyle change, scaling up effective programs to increase access, working with advocacy partners, and using a systems-based approach. The CDC's Diabetes strategic plan for 2017-2021 includes 3 major goals and the corresponding strategies for each goal: 5 The vast majority of DM care is overseen by primary care physicians who may also be treating these patients for high cholesterol, hypertension, and other chronic conditions. 6 There are also many community risk factors for developing these cardiometabolic conditions, such as poor diet, physical inactivity, excessive alcohol use, smoking, lower socioeconomic status, access to nutritious foods, and education level. Some of the biggest barriers to managing these disease conditions are age; genetics; cultural bias (on the part of both patient and provider); social determinants and environmental factors; lack of access to healthy options; improperly addressed prediabetes; access to quality health care; cost of medicine; and the need for major lifestyle changes. Factors shown to reduce the risk of developing these diseases are smoking cessation, cultural competency training, increasing education, affordable health care, and lifestyle changes. As demographics change in the United States, the population is projected to be 29% Hispanic by 2060. 7 Thus, future public health professionals will need to place a larger emphasis on primary and secondary prevention through culturally sensitive approaches. For example, they should emphasize the DASH diet and the AHA Recommended Dietary Guidelines without dismissing traditional foods. Healthcare providers must overcome stereotypes about populations while also encouraging intake of fresh vegetables, whole grains, lean poultry, fish, and fruit. Health professionals will also need to focus on improving access to health care-again while addressing stereotypes. Strategies include engaging primary care providers, addressing physiological and social factors, improving access to quality care, addressing social determinants of health, making small changes, and meeting people "where they are." evolving. Some medications show favorable effects on cardiovascular outcomes in patients with DM and CVD; promising results have been recorded in cardiovascular death, heart attack, stroke, renal disease, and heart failure. The evidence base for favorable cardiovascular outcomes for these DM medications is growing. However, many additional questions still need to be addressed before evidence-based recommendations can be implemented and widespread adoption can occur. Providers and specialists are still trying to understand how to interpret these clinical trial results, and to determine which patients are the best candidates for certain types of medications. Among the clinical questions are the following:
1. Which medications, if any, should be given to patients with prediabetes? 2. Who should make the treatment decisions and monitor for safety and side effects-the primary care physician, healthcare provider, endocrinologist, or the diabetologist? 3. What are the implications of these medications on healthcare costs?
Many of these questions must be addressed before current guidelines and reimbursement models can change, and before providers are likely to change their behavior.
Barriers to Clinical Management of DM Along the Lifespan
Individuals with type 1 DM have unique challenges to diagnosis and treatment. The diagnosis can be confusing, as >40% of patients are diagnosed after age 30 years. 8 Individualized treatment plans with specialists are paramount to avoid severe complications of hyper-and hypoglycemia. There is not much evidence on what role, if any, the newer drug classes may have on CVD outcomes, and there is a substantial cost to caring for a patient with type 1 DM . Similarly, there are many barriers in the diagnosis and treatment of individuals with type 2 diabetes mellitus (T2DM). There is confusion among healthcare professionals on which test is best to screen for and to diagnose T2DM (eg, hemoglobin A1c, oral glucose tolerance test, or fasting blood glucose). When does the relationship between impaired glucose metabolism and CVD risk begin? Weight loss is central to decreasing DM and prediabetes. However, it is very challenging for most patients. The treatment for T2DM is complex and changing quickly as additional clinical trials report on results. Clinical confusion exists on what should be first-, second-, and third-line agents for these patients. Also, the cost of newer drugs makes choices more limited for many. There is a need for better guidance for providers on when to use these medications.
DM Prevention, Diagnosis, and Treatment Using a Population Systems Approach
Kaiser Permanente is a large healthcare organization that uses a systems-based approach for prevention, diagnosis, and treatment of patients with DM. First, Kaiser's approach set a few simple, measurable treatment targets and continually monitors these measures. Second, treatment intensification of every patient was encouraged where possible. This is accomplished using a team-based accountability model, developing a single treatment algorithm that covers 80% of patients with T2DM and allowing the provider some level of treatment personalization and intensification (through titration, initiation, and adherence). The last step is to measure, give providers feedback, and correct treatments until all targets are met.
The simplified treatment algorithm approach to prevent CVD has been successful. In 2004-2005, 70 000 patients with T2DM or CVD were treated using this algorithm and followed for 2 years. Their outcomes were compared with 170 000 control patients whose providers did not use the treatment algorithm during a similar time period. The study showed a 60% reduction in heart attacks and strokes in the low-adherence to treatment algorithm group and an 80% reduction in these same outcomes in the high-adherence to treatment algorithm group. 9 Glycemic control has been more challenging to implement, but again the simplified treatment algorithm approach has been successful in helping to manage patients with T2DM. Kaiser also screens all patients 45 years or older for DM every 3 years, and uses hemoglobin A1c as the screening tool. In addition, patients have the option to enroll in the DPP and/or a weight-loss program for patients with prediabetes. Table 2 outlines key solutions for healthcare systems and quality improvement identified during the breakout discussions.
Panel 2: Prevention Through Increasing Patient Awareness Around Cardiometabolic Risk and Empowering Individuals to be Engaged in Their Care Complex Needs of Patients Living With Cardiometabolic Disorders
Patients face many challenges in managing DM. Patient noncompliance with treatment is a major issue; Barriers to treatment include the following:
1. Difficulty consistently taking and adhering to medications because of the high cost of medications and glucosetesting supplies (eg, testing strips, lancets), addiction to drugs and alcohol, physical impairment, and blindness.
2. Socioeconomic issues can have a significant impact on lifestyle and compliance with treatment when they are deprioritized because of factors such as low household income, inadequate family support, lack of trust in the medical community, and lack of resources (including mental health, transportation) are more immediate concerns. 3. Food deserts limit access to fresh fruits and vegetables and encourage unhealthy food selection (eg "junk food") at "corner store"-type retailers. Lack of available food choices can also lead to higher consumption of fast food, which may not be as nutritious as fresh food choices and can lead to obesity. 4. Poor health literacy and limited access to health education programs (eg, DPP, Diabetes Self-Care Management Education and Support, heart-health education classes).
One strategy is to find ways to empower patients to take ownership of their health care. Encouraging cultural sensitivity and meeting people where they are, and in their preferred language, are also crucial to making a lasting impact in patient engagement. It is important to consider different models for success in DM and heart-health management, and to consider nontraditional places for education, prevention, and care (eg, places of worship). There are also numerous free local and federal government outreach programs that are available to educate patients about DM. Finally, nurses and other healthcare providers are integral to the care process for these patients and can provide many of these key solutions for patients in their homes, in the language with which they are comfortable, and in a culturally sensitive and relevant way.
Challenges in Identifying Individuals With Prediabetes and Those at Risk in Adults and Children
Lack of clarity for the role of screening and treatment guidelines for prediabetes and DM may be sources of confusion in the DM clinical care community. Summit participants discussed the differing definitions for prediabetes, DM, and screening test thresholds. The AHA and American Diabetes Association define prediabetes at either a hemoglobin A1c level between 5.7% and 6.4%, fasting blood glucose between 100 and 125 mg/dL, or an oral glucose tolerance test 2-hour blood glucose between 140 and 199 mg/dL. Additionally, the AHA and American Diabetes Association classify DM as a hemoglobin A1c ≥6.5%, fasting blood glucose ≥126 mg/dL, or oral glucose tolerance test 2-hour blood glucose ≥200 mg/dL. Conversely, the World Health Organization primarily uses impaired fasting glucose and impaired glucose tolerance and does not have a category for people with prediabetes. It is possible to have discordant results between these 3 tests, which leaves the patient and provider to determine whether the patient would be considered to have prediabetes. Within the pediatric community, another controversy exists around screening test thresholds and which factors should be included. A recent study showed that hemoglobin A1c alone is a poor discriminator of prediabetes in obese and overweight youth. 10 There is uncertainty surrounding the best predictors for prediabetes in this population. There are also differences in how providers treat and address people with prediabetes and DM. Experts questioned when to add medications to a treatment regimen. In many cases, for patients with prediabetes, the focus should be on lifestyle change. There is also a need to shift the conversation from defining patients with prediabetes to a focus on their "higher risk for diabetes mellitus," which may create greater urgency around lifestyle and treatment changes if required. In addition, simple interventions that remind and empower patients to advocate for their care (and parents to ask their child's provider about their child's health) are also very important.
Challenges and Opportunities in Supporting Undertreated Audiences in Risk Management
African-Americans, Hispanics, and American Indians/Alaskan Natives are disproportionately affected by DM. 2 These racial and ethnic groups face unique challenges with diet, lifestyle, racism, and self-management. Opportunities for combatting these issues include culturally sensitive and culturally tailored programming, using certified DM educators who can communicate in a patient's native language where needed, incorporating the family unit into the education process, and promoting family-based learning about health conditions. It is a combined approach of prevention (eg, publicizing advantages of exercise, calorie restriction, blood pressure control), protection (eg, need for safe housing, food, travel, and water), and partnerships (eg, government agencies, providers, public/private corporations, pharmaceutical manufacturers, and community organizations).
Effective Strategies to Motivate Lifestyle Changes, Evaluation, and Counseling
To effectively motivate patients' lifestyle changes, it is important to uncover individual motivators (eg, competition, major events in life) and demotivators (eg, depression, financial stress). Providers who can engage in a meaningful conversation with the patient can help that individual develop a meaningful treatment plan. Some questions providers should consider when discussing DM with patients are the following:
1. What are your barriers to success? (eg, food insecurity, change in routine, cultural beliefs). 2. What is considered success for you? (eg, pounds lost, clothing size, better decisions, tracking food intake). 3. What are the risks and benefits to making this change?
(eg, cost, time commitment).
Providers who can counsel patients will help support successful outcomes and compliance. Those dialogues could include sharing successes, mitigating patient expectations, being realistic about goals, and including cut points throughout the process to ensure patients remain on track.
Complications From DM in Addition to CVD and Stroke
While CVD is the leading cause of mortality for individuals with DM, amputations are a significant complication of poorly controlled DM. Simple no-cost and low-cost interventions have been shown to make positive differences in outcomes. Education and communication materials such as fliers in provider offices that promote daily foot checks and good Create educational curriculum and training tools for all healthcare providers (eg, physicians, nurses, physician assistants, DM educators) on behavior change, motivational interviewing, shared decision-making, and listening to their patients Develop talking points and educational resources for providers on out-of-pocket costs for long-term DM care
Better equip and position healthcare providers to counsel on behavior change techniques from a family-focused vs individual approach, and provide simple pathways for referral to other members of the team with this expertise Encourage providers to ask about diet, activity, and social determinants of health, and provide skill development with small, attainable goals Having patients come to providers' offices for toenail clipping, along with foot exams, has also been shown to be effective. Table 3 outlines key solutions for patient education, engagement, and empowerment identified during the breakout discussions. Barriers to health for some patients with cardiometabolic conditions include lower income, disparities in care, cultural insensitivity, literacy levels, lack of social support, pill burden, medication and diabetic supply costs, no access to regular care, difficulty getting to appointments, lack of sidewalks, lack of access to grocery stores, and multiple job and family responsibilities. Utilizing a team of healthcare providers such as nurses or DM educators may present a viable solution to addressing some of these barriers. There are more than 2.85 million nurses across the United States who could be activated to educate patients about DM, prediabetes, and metabolic syndrome through a variety of venues and audiences. 11 In addition, there are certificate programs available through organizations such as the Preventative Cardiovascular Nurses Association to help train providers in behavior change. This certification includes information on how to perform cardiovascular risk assessments using individualized tools and high-risk communication strategies, and develops an introduction to motivational interviewing and coaching. This includes how to select and implement behavior change strategies with patients including developing goals, planning for behavior change, and evaluating goal completion. Ultimately, all providers must be able to effectively identify and assess CVD risk factors, implement treatment plans, and incorporate lifestyle and pharmacologic therapy for their patients.
Advancing Cardiometabolic Health Through Community-Based Programs
The National DPP, Diabetes Self-Care Management Education and Support, and the Chronic Disease Self-Management Program, among others, have been effective in helping patients prevent, treat, and manage their DM or prediabetes. 12 Building community-clinic linkages are increasingly important in achieving desired health outcomes and supporting those with DM and cardiometabolic disorders. This can move traditional hospitalbased programs to the community and make use of communitybased health workers to implement them. This may allow physicians to offer services where their patients reside, work, or worship; and this aligns with value-based healthcare trends; potentially increases insurance coverage to offset patient expenses; and might help achieve the aims of better access to care, better outcomes, and lower costs. Community-based organizations also are seeing the value in partnering with healthcare organizations by using established programs (eg, National DPP), data collection mechanisms, and reporting for recognition/certification as well as increased reimbursement. The major barriers to these linkages are lack of provider awareness of these programs and lack of information provided by community partners on the care and outcomes achieved from these programs. These barriers can be overcome through increased communication between partners.
The Role of Health-Tech in Cardiometabolic Health
There are more than 250 000 health mobile applications available in the marketplace; however, there are no specific standards on what information is collected, how these data are stored and used, and the potential uses of applications. The AHA's Center for Health Technology and Innovation is working to overcome barriers in the adoption of technology. These barriers can be divided into 3 groups:
1. Patients (when to use the apps/wearables, which is the right product, validation and reliability, how to interpret and apply the data). 2. Digital device and app companies (defining the use case, understanding patient/provider needs, incorporating into clinical care). 3. Clinicians, insurers, health systems, and pharmaceutical manufacturers (inertia/sharing control, need for evidence, incorporating the health tech data collected into workflows, IT implementation, and reimbursement issues).
It is important to align the science with the products and build care plans that can be used with a wide range of technologies. The AHA is using its core statements and guidelines to create care plans, algorithms, and health education content items for health technology companies. Better understanding of what technology patients can access and how to connect these technologies to the health record will help AHA and others support viable solutions. The concept of "health techquity" was introduced: the intersection between better screening for DM and finding the simplest available technology to better serve people with DM and prediabetes. This is in effect looking to use the cheapest, most scalable technologies rather than trying to implement an expensive, difficult-to-access solution. Table 4 outlines key solutions for community-based interventions and health technology identified during the breakout discussions.
Discussion
Through an electronic voting process for attendees, the key factors and proposed solutions in the 3 panels were further prioritized for AHA to consider after the Cardiometabolic Health and Diabetes Summit ( Table 1) .
The solutions presented throughout the Cardiometabolic Health and Diabetes Summit fall within each of these categories. Each "puzzle" piece has its own potential barriers that need to be addressed to efficiently and effectively help patients and families manage cardiometabolic risk factors and prevent CVD. Figure 3 shows the interplay between the different solutions that have been presented to help advance the care of people with prediabetes, DM, and cardiometabolic disorders. The patient is the central piece of the "puzzle" as we work to better manage CVD and cardiometabolic risk. The 4 central factors that directly impact the patient and his/her health outcomes are as follows: community in which he/she lives; social determinants of health that impact the patient's life; family members (who are integral to the diet/lifestyle and genetic predisposition); and the healthcare team that helps the patient manage risk factors. Secondary factors that play an important role in the patient managing cardiometabolic risk factors and health outcomes are as follows: advocacy and payers; systems of care; approaches from the inpatient and outpatient settings; and health technology and science/research. Ultimately, there is much more work that will need to be done in this area to complete the puzzle and align these factors together to transform the way in which patients with DM and cardiometabolic risk factors are diagnosed, treated, and managed in the United States.
Conclusion
The multidisciplinary group of professionals, providers, patients, and organizations at the Cardiometabolic Health and Diabetes Summit has set the stage for a new initiative that will begin to pull these disparate puzzle pieces together and to generate a cohesive vision and strategy for the future. As further research is conducted in the basic, clinical, and population health spaces, the link between DM, cardiometabolic risk, and CVD becomes strengthened and the need for a comprehensive approach to identification, treatment, management, and prevention is more apparent. In order to change the trajectory of the ever-growing numbers of people who will develop DM and other cardiometabolic conditions, AHA along with the DM community can and must solve this "complex puzzle" in order to tackle this national issue and decrease mortality from DM and CVD.
